A Psychedelic Depression Drug Met Its Main Trial Goal. How Much Did It Help?

Helus Pharma’s Depression Drug Showed a Difference by Day Two. What About Week 12?

Two Psychedelic Doses Alongside an Antidepressant. How Long Did the Relief Last?

At Six Weeks, About Half The People Given HLP003 Were In Remission.

Out of every 100 people taking their usual antidepressant, about 51 reached remission when researchers added the experimental psychedelic drug HLP003. With a placebo and the same psychological support, about 18 in 100 did. That difference, roughly 33 additional people in remission for every 100 treated, is the clearest way to understand the results Helus Pharma announced on 16 November 2026.

The phase 3 trial, called APPROACH, also met its main goal. Six weeks after the first dose, depression scores had fallen by an estimated 19.5 points in the HLP003 group and 11.9 points in the placebo group. The extra improvement averaged 7.6 points. By week 12, the two groups were still separated by seven points, although fewer people in either group qualified as being in remission.

What Did Participants Actually Receive?

HLP003, previously called CYB003, is a modified form of psilocin, the substance responsible for the psychedelic effects of magic mushrooms. Helus is developing it for people who still have substantial symptoms of depression while taking an antidepressant. For someone who has had some benefit from their existing prescription, the distinction matters. The study tested what happened when people kept taking it and added a course of treatment.

The analysis included 222 adults with moderate to severe major depressive disorder. Researchers randomly assigned 112 to HLP003 and 110 to a matching inactive placebo. Participants attended two dosing sessions about three weeks apart. The active group received 16 milligrams at each session. Both groups continued their existing medication at a stable dose and received psychological support throughout the study.

That design answers a fairly specific question. Someone deciding between adding HLP003 and switching to a different antidepressant would need evidence comparing those choices directly. Someone considering taking mushrooms at home would be looking at a different substance, setting and level of support from the treatment studied here.

What Does a 7.6-Point Difference Feel Like?

Researchers used the Montgomery–Åsberg Depression Rating Scale, often shortened to MADRS. A clinician rates ten aspects of depression, including sleep, appetite, concentration and the ability to feel pleasure. The total runs from zero to 60. Two people can have the same score for quite different reasons. One might be sleeping better and still find little to enjoy. Another might regain interest in seeing friends while continuing to struggle with sleep.

Participants began with average scores close to 33 in both groups. The six-week changes of 19.5 and 11.9 points are estimated group averages. They cannot tell an individual which symptoms are likely to ease first. And the considerable improvement in the placebo group is precisely why the comparison matters. Some people’s symptoms change with time, and everyone in this trial continued to receive care. The design does not tell us how much each of those factors contributed.

Two other measures bring the result closer to an individual experience. A response meant a person’s score fell by at least half. At six weeks, 56.3% of the HLP003 group and 28.2% of the placebo group met that mark. Remission meant a score of ten or below. The figures were 50.9% and 18.2%, respectively.

Consider someone who entered with a score of 34. A fall to 17 would be enough for a response, even though that person could still be experiencing considerable difficulty. A score of ten would qualify as remission and could still include some symptoms. Neither threshold tells us whether that person was back at work or felt like themselves again. It tells us what a clinician could establish at that visit.

How Much of the Benefit Lasted?

The first difference appeared on day two, before the second dosing session. By then, half the people assigned to HLP003 had seen their score fall by at least half, compared with just under a quarter on placebo. For a treatment intended for people who are already taking medication and still feel unwell, the possibility of relief that early deserves attention.

The six-week assessment captured the effect after both planned sessions. At week 12, 40.2% of the HLP003 group were in remission, compared with 15.5% on placebo. In practical terms, the advantage had narrowed from around 33 additional remissions per 100 people at week six to around 25 at week 12.

Those figures are snapshots. Subtracting one visit’s remission rate from the next cannot tell us exactly how many individuals relapsed. Some people may have improved later while others lost an earlier benefit. Following individuals over time is what would tell a patient how long relief typically lasts after they first experience it.

The Difficulty of Testing a Psychedelic Against Placebo

APPROACH was double-blind, meaning treatment assignments were concealed. A psychedelic presents an unusual problem for that arrangement. Even when two capsules look identical, a noticeable change in perception can give someone a clue about which one they swallowed. The absence of that experience may give someone in the placebo group a clue of their own.

Expectations can then influence how a participant describes their symptoms or how an observer interprets a change. The US Food and Drug Administration has highlighted this problem in its guidance on psychedelic trials. Helus’s initial written results give no measure of how accurately APPROACH participants guessed their assignments. That leaves an uncertainty about the size of the advantage, even with a statistically significant difference between groups.

Three Serious Events and a Second Trial

Helus said most adverse events were mild or moderate, passed quickly and occurred on dosing days. It also reported three serious adverse events that investigators considered related to HLP003. The written announcement did not describe those events individually. Their nature, timing and consequences matter to anyone weighing the chance of relief against the risks of treatment.

HLP003 remains experimental. A second pivotal study, EMBRACE, is comparing two dose levels with placebo. Helus expects initial results in the final quarter of 2027. A separate extension, EXTEND, is following participants for longer and examining what happens when some receive further doses.

For someone whose antidepressant has helped only partly, those studies address the decisions the first trial leaves open. Could a lower dose offer similar relief? If symptoms return, does another course help, and at what risk? APPROACH gives patients a concrete six-week estimate. What they still need is a reliable account of what happens after a good six weeks.

Sources

Next Reads

Previous
Previous

Voyager 1 Is About to Reach One Light-Day From Earth. How Long Does NASA Wait for a Reply?

Next
Next

How Can a Glacier Disappear While the Ice Is Still There? NASA’s Images From Indonesia